Unjoni Ewropea - Malti - EMA (European Medicines Agency)

intervet international bv - leptospira interrogans serogrupp canicola serotip portland-vere (razza ca-12-il 000), l. interrogans serogrupp icterohaemorrhagiae serotip copenhageni (razza ic-02-001), l. interrogans serogrupp ma ' serotip bratislava (razza bħala-05-073), l. kirschneri serogrupp grippotyphosa serotip dadas (razza gr-01-005) - immunoloġiċi - klieb - għall-immunizzazzjoni attiva tal-klieb kontra:leptospira interrogans serogrupp canicola serotip canicola biex tnaqqas infezzjoni u tneħħija fl-awrina;l. interrogans serogrupp icterohaemorrhagiae serotip copenhageni biex tnaqqas infezzjoni u tneħħija fl-awrina;l. interrogans serogrupp ma ' serotip bratislava biex titnaqqas l-infezzjoni;l. serogrupp kirschneri grippotyphosa serovar bananal / lianguang biex inaqqas l-infezzjoni u l-eskrezzjoni ta 'l-awrina.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid - meninġite, meningokokkali - vaċċini - nimenrix huwa indikat għall-immunizzazzjoni attiva ta 'individwi mill-età ta' 6 ġimgħat kontra mard invażiv meningokokkali kkawżat minn neisseria meningitidis grupp a, c, w-135, u y.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

serono europe limited - efalizumab - psorajiżi - immunosoppressanti - trattament tal-pazjenti adulti ma moderat biex psoriasis plakka kronika severi li jkunu naqqsu milli jwieġbu għal, jew li jkollhom a contraindication li, jew li huma intolerant li t-terapiji sistematiċi oħra inklużi ciclosporin, methotrexate u puva (ara taqsima 5. 1 - effikaċja klinika).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck europe b.v.  - interferon beta-1a - sklerosi multipla - immunostimulanti, - rebif hu indikat għall-kura ta': pazjenti b'avveniment wieħed demyelinating bi proċess infjammatorju attiv, jekk dijanjosi alternattivi kienu esklużi, u jekk kien stabbilit li huma f'riskju għoli li jiżviluppaw sklerożi multipla klinikament definita;il-pazjenti li jkollhom sklerożi multipla reċidiva. fi provi kliniċi, dan ġie karaterizzat jew aktar l-aggravament akut fil-sentejn preċedenti. l-effikaċja ma ntwerietx f'pazjenti bi sklerożi multipla progressiva sekondarja mingħajr għaddejjin irkadar.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

alexion europe sas - eculizumab - emoglobinurja, paroxysmal - immunosoppressanti - soliris huwa indikat fl-adulti u t-tfal għall-kura ta': emoglobinurja notturnali parossimali (pnh). l-evidenza ta 'benefiċċju kliniku hija murija f'pazjenti b'emodijalisi ma' sintomi kliniċi(i) indikattiv ta'l-attività għolja tal-marda, irrispettivament mill-trasfużjoni-istorja (ara sezzjoni 5. atipiċi sindromu uremiku emolitiku (ahus). soliris huwa indikat fl-adulti għall-kura ta': ġeneralizzati refrattarji myasthenia gravis (gmg) f'pazjenti li huma kontra l-acetylcholine-riċettur (achr) antikorpi pożittivi (ara sezzjoni 5. neuromyelitis maws ottiku għall-logħob tal-ispettru disturb (nmosd) f'pazjenti li huma kontra l-aquaporin-4 (aqp4) antikorpi pożittivi bl-isklerożi multipla reċidiva-kors tal-marda.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - emoglobinurja, paroxysmal - immunosuppressanti selettivi - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - pegcetacoplan - emoglobinurja, paroxysmal - immunosoppressanti - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

samsung bioepis nl b.v. - eculizumab - emoglobinurja, paroxysmal - immunosoppressanti - epysqli is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

amgen technology (ireland) uc - eculizumab - emoglobinurja, paroxysmal - immunosoppressanti - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). l-evidenza ta 'benefiċċju kliniku hija murija f'pazjenti b'emodijalisi ma' sintomi kliniċi(i) indikattiv ta'l-attività għolja tal-marda, irrispettivament mill-trasfużjoni-istorja (ara sezzjoni 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer limited - virus ta 'l-influwenza tat-tjur inattivat rikombinanti - immunoloġiċi - chicken; ducks - għal immunizzazzjoni attiva ta 'tiġieġ u papri kontra l-virus ta' l-influwenza tat-tjur tat-tip a, sottotip h5. tiġieġ: tnaqqis tal-mortalità u l-eskrezzjoni tal-virus wara l-isfida. il-bidu tal-immunità: 3 ġimgħat wara t-tieni injezzjoni. it-tul ta 'żmien tal-immunità fit-tiġieġ għadu ma ġiex stabbilit. papri: tnaqqis ta ' sinjali kliniċi u eskrezzjoni tal-virus wara sfida. il-bidu tal-immunità: 3 ġimgħat wara t-tieni injezzjoni. tul tal-immunità fil-papri: 14-il ġimgħa wara t-tieni injezzjoni.